Roche Third-Quarter Sales Rise on Sales of New Medicines

The video discusses Rush's sales performance, highlighting a sales figure of 34.8 billion Swiss francs against an estimate of 35.5 billion. It covers the FDA approval of a significant drug, which was a key factor in an $8 billion acquisition. The video also breaks down sales in pharmaceuticals and diagnostics, confirming solid growth and a positive outlook for 2014. Additionally, it mentions Rush's debt reduction strategy and potential future deals.

What were the total sales delivered by Rush for the nine months?

What significant approval did Rush receive from the FDA?

What was the value of the interim deal Rush made earlier in the year?

What is the estimated sales figure that the market is looking for in diagnostics?

What percentage has Rush reduced its debt to equity ratio?